Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

arges - 5,367 - 5,367

Net loss, non-GAAP $(4,294) $(39,045) $(36,193) $(94,101)

Basic and diluted net loss

per share, as reported $(0.07) $(0.97) $(0.60) $(1.91)

Adjustments $- $0.31 $- $0.31

Basic and diluted net loss

per share, non-GAAP** $(0.07) $(0.66) $(0.60) $(1.59)

Shares used in computing

basic and diluted net loss

per share 60,856 59,223 60,706 59,089

**The values shown above are exact; totals may not appear to sum due to rounding

CONSOLIDATED BALANCE SHEET DATA

(In Thousands)

(Unaudited)

June 30, 2008 December 31, 2007

Assets:

Cash, cash equivalents, and

marketable securities $272,313 $174,245

Other current assets 40,874 41,825

Total current assets 313,187 216,070

Property and equipment, net 16,639 19,131

Other assets 20,815 23,635

Total assets $350,641 $258,836

Liabilities and stockholders' deficit:

Current liabilities $46,534 $39,183

Convertible subordinated notes 346,500 399,500

Deferred revenue 159,805 -

Other long-term obligations 4,675 5,551

Stockholders' deficit (206,873) (185,398)

Total liabilities and stockholders'

deficit $350,641 $258,836


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, ... data capture (EDC) solutions for clinical trials, today announced that ... Research Organization (CRO) to provide eClinical solutions for a pivotal ... studies serve to establish the safety and efficacy of investigational ...
... , ANNAPOLIS, Md., Aug. 13 PharmAthene, ... medical countermeasures against biological and chemical threats, today reported financial and ... 30, 2009. , , For the second quarter ... million in the same period of 2008. For the six ...
... CHENGDU, China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., ... and supplier of,modernized traditional Chinese medicine ("TCM") based in ... the Chinese State Food and Drug,Administration (SFDA) to produce ... number Z20093512) and Yinqiao Jiedu Tablets in,dosage form of ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... two Queens scientists has resulted in an exciting new method ... weapons and pesticides. Recently completed testing by an independent ... greater than 99 per cent effective when used on the ... in solution, full destruction of all three agents was achieved ...
... American farmers. In spite of their use in the ... freeze (19982004) on growing and importing transgenic crops., In ... by the recipient governments. The EUs stand on agricultural ... Unruh Snyder, Department of Agronomy, Purdue University, along with ...
... specialists for cancer treatment in developing countries is a driving ... change the health-care picture over time. The course - in ... the Asia and Pacific region through partners working with the ... of radiotherapy, which plays a positive role in the care ...
Cached Biology News:Queen's develops safe 'green' decontamination method 2Distance learning course in radiation oncology for cancer treatment 2
... 30 isolations. The kit provides a ... apoptotic cells from normal c lture using ... is a Ca2+-dependent phospholipid binding protein with ... Cell Isolation Kit provides a simple and ...
... diameter, 7 inch long PYREX NMR tubes are ... ground joints, valves, and vacuum racks. They are ... 300 to 500MHz. They have an O.D. of ... + 0.013-0.000mm. These NMR tubes can be used ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The GenElute Gel Extraction Kit combines silica- ... or vacuum column format. DNA fragments of interest ... by solubilizing the gel. The Gel Solubilization Solution ... run in either TBE or TAE buffer. Extracted ...
Biology Products: